Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Hungary: These 33 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Hungary: These 33 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can ZYKADIA (ceritinib) generic drug versions launch in Hungary?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Hungary Patent S1500049

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can LETAIRIS (ambrisentan) generic drug versions launch in Hungary?

Generic name: ambrisentan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Hungary Patent E025355

LETAIRIS is a drug marketed by Gilead. There are three patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering LETAIRIS

See drug price trends for LETAIRIS.

The generic ingredient in LETAIRIS is ambrisentan. Additional details are available on the ambrisentan profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in Hungary?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Hungary Patent E027896

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in Hungary?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Hungary Patent E053098

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in Hungary?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Hungary Patent S1800010

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in Hungary?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: Hungary Patent E020998

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Hungary?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Hungary Patent E047422

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Hungary?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Hungary Patent E026168

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Hungary?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Hungary Patent E026168

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can PRESTALIA (amlodipine besylate; perindopril arginine) generic drug versions launch in Hungary?

Generic name: amlodipine besylate; perindopril arginine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 26, 2027
Generic Entry Controlled by: Hungary Patent E027898

PRESTALIA is a drug marketed by Adhera. There is one patent protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering PRESTALIA

The generic ingredient in PRESTALIA is amlodipine besylate; perindopril arginine. Additional details are available on the amlodipine besylate; perindopril arginine profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in Hungary?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Hungary Patent S2100001

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can AMYVID (florbetapir f-18) generic drug versions launch in Hungary?

Generic name: florbetapir f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 26, 2027
Generic Entry Controlled by: Hungary Patent E032660

AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug. There has been litigation on patents covering AMYVID

The generic ingredient in AMYVID is florbetapir f-18. Additional details are available on the florbetapir f-18 profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Hungary?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Hungary Patent E026145

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Hungary?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Hungary Patent E027630

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Hungary?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Hungary Patent E055205

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Hungary?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Hungary Patent E027209

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Hungary?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Hungary Patent E072202

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in Hungary?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Hungary Patent 700,339

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in Hungary?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Hungary Patent 230,748

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in Hungary?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Hungary Patent E034796

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in Hungary?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Hungary Patent P0700339

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in Hungary?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Hungary Patent E046490

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Hungary?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Hungary Patent E031550

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Hungary?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Hungary Patent E040391

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Hungary?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Hungary Patent E031550

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Hungary?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Hungary Patent E040391

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Hungary?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Hungary Patent E029236

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Hungary?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Hungary Patent E043732

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can EMBEDA (morphine sulfate; naltrexone hydrochloride) generic drug versions launch in Hungary?

Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Hungary Patent E031590

EMBEDA is a drug marketed by Alpharma Pharms. There are seven patents protecting this drug and four Paragraph IV challenges.

See drug price trends for EMBEDA.

The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in Hungary?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Hungary Patent E025909

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Hungary?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Hungary Patent E030519

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Hungary?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 01, 2027
Generic Entry Controlled by: Hungary Patent E067736

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Hungary?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Hungary Patent E026206

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Hungary?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Hungary Patent E026507

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Hungary?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Hungary Patent E044237

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Hungary?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Hungary Patent S2500052

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch in Hungary?

Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 09, 2027
Generic Entry Controlled by: Hungary Patent E029145

Drug Price Trends for DAKLINZA
DAKLINZA is a drug marketed by Bristol-myers Squibb. There are five patents protecting this drug. There has been litigation on patents covering DAKLINZA

See drug price trends for DAKLINZA.

The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. Additional details are available on the daclatasvir dihydrochloride profile page.

When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch in Hungary?

Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 09, 2027
Generic Entry Controlled by: Hungary Patent E037802

Drug Price Trends for DAKLINZA
DAKLINZA is a drug marketed by Bristol-myers Squibb. There are five patents protecting this drug. There has been litigation on patents covering DAKLINZA

See drug price trends for DAKLINZA.

The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. Additional details are available on the daclatasvir dihydrochloride profile page.

When can LOCAMETZ (gallium ga-68 gozetotide) generic drug versions launch in Hungary?

Generic name: gallium ga-68 gozetotide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 17, 2027
Generic Entry Controlled by: Hungary Patent E047200

LOCAMETZ is a drug marketed by Novartis. There are two patents protecting this drug.

See drug price trends for LOCAMETZ.

The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. Additional details are available on the gallium ga-68 gozetotide profile page.

When can VIZAMYL (flutemetamol f-18) generic drug versions launch in Hungary?

Generic name: flutemetamol f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 30, 2027
Generic Entry Controlled by: Hungary Patent S1500007

VIZAMYL is a drug marketed by Ge Healthcare. There is one patent protecting this drug.

See drug price trends for VIZAMYL.

The generic ingredient in VIZAMYL is flutemetamol f-18. Additional details are available on the flutemetamol f-18 profile page.

When can PYLARIFY (piflufolastat f-18) generic drug versions launch in Hungary?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2027
Generic Entry Controlled by: Hungary Patent E039199

PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.

See drug price trends for PYLARIFY.

The generic ingredient in PYLARIFY is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY (piflufolastat f-18) generic drug versions launch in Hungary?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2027
Generic Entry Controlled by: Hungary Patent E059645

PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.

See drug price trends for PYLARIFY.

The generic ingredient in PYLARIFY is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY TRUVU (piflufolastat f-18) generic drug versions launch in Hungary?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2027
Generic Entry Controlled by: Hungary Patent E039199

PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.

The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY TRUVU (piflufolastat f-18) generic drug versions launch in Hungary?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2027
Generic Entry Controlled by: Hungary Patent E059645

PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.

The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Hungary?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Hungary Patent E031293

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Hungary?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Hungary Patent E041429

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can ZEMDRI (plazomicin sulfate) generic drug versions launch in Hungary?

Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 21, 2027
Generic Entry Controlled by: Hungary Patent E030523

ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug. There has been litigation on patents covering ZEMDRI

See drug price trends for ZEMDRI.

The generic ingredient in ZEMDRI is plazomicin sulfate. Additional details are available on the plazomicin sulfate profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in Hungary?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2027
Generic Entry Controlled by: Hungary Patent E028773

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in Hungary?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: Hungary Patent E031913

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in Hungary?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: Hungary Patent E049642

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in Hungary?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: Hungary Patent S2000030

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in Hungary?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: Hungary Patent E053904

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

When can ONPATTRO (patisiran sodium) generic drug versions launch in Hungary?

Generic name: patisiran sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 27, 2027
Generic Entry Controlled by: Hungary Patent E034483

ONPATTRO is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug. There has been litigation on patents covering ONPATTRO

See drug price trends for ONPATTRO.

The generic ingredient in ONPATTRO is patisiran sodium. Additional details are available on the patisiran sodium profile page.

Hungary Branded and Generic Drug Market Assessment: Regulatory Opportunities, Patent Risks and Commercial Outlook

Last updated: October 11, 2026

Hungary is a price-sensitive, reimbursement-driven pharmaceutical market with strong generic penetration and centralized public purchasing. Branded products retain value in specialty care, hospital medicines, oncology, immunology, diabetes and high-cost biologics. Generic manufacturers benefit from a mature substitution framework, but face aggressive price referencing, mandatory discounts, public reimbursement controls and a domestic “clawback” burden. Regulatory opportunities are strongest in generics, biosimilars, specialty medicines, shortages management, local manufacturing and EU-wide centralized approvals.

What is the size and structure of the Hungarian pharmaceutical market?

Hungary has a population of about 9.6 million and operates a predominantly publicly financed healthcare system. The National Health Insurance Fund Administration, known as NEAK, is the central payer for reimbursed medicines. Retail pharmacy sales and hospital procurement follow different commercial and regulatory models.

Market segment Main purchasing route Principal decision-maker Commercial characteristics
Reimbursed outpatient medicines Community pharmacies NEAK, prescribers, patients Reference pricing, patient co-payments, generic substitution
Non-reimbursed retail medicines Community pharmacies and retailers Consumers Brand, availability and pharmacy recommendation influence demand
Hospital medicines Tendering, framework procurement and managed access Hospitals, NEAK, public procurement bodies Price competition, budget caps and tender concentration
High-cost specialty medicines Individual reimbursement, tenders or special programs NEAK and specialist institutions Evidence, budget impact and negotiated access are decisive
Vaccines and public-health products Public tenders and state programs National public-health authorities Volume procurement and centralized purchasing

Hungary spends less on health than the EU average as a share of gross domestic product. Out-of-pocket spending remains material, which makes patient co-payment and retail affordability important factors in brand selection and treatment persistence (OECD, 2023).

The pharmaceutical market is divided between multinational originator companies, regional generics manufacturers and Hungarian producers. Richter Gedeon is the largest domestic pharmaceutical group and has substantial branded-generics, specialty and biosimilar capabilities. Other important market participants include Egis, Teva, Sanofi, Novartis, Bayer, Sandoz, Viatris, Zentiva, KRKA, Servier, Novo Nordisk, AstraZeneca and Roche.

How do branded drugs compete in Hungary?

Branded medicines compete through reimbursement status, clinical differentiation, prescriber access, supply reliability and co-payment positioning. Patent protection alone does not guarantee commercial exclusivity because Hungary applies EU pharmaceutical rules and can approve competing products after the relevant regulatory and intellectual-property barriers expire.

Originator companies generally pursue one or more of four strategies:

  1. Obtain national reimbursement after centralized or national marketing authorization.
  2. Maintain a premium position through clinical evidence or a differentiated delivery system.
  3. Use risk-sharing or managed-entry arrangements for high-cost medicines.
  4. Shift demand toward line extensions, fixed-dose combinations or specialty indications.

Brand value is strongest where treatment decisions are specialist-led or where substitution is clinically sensitive. Oncology, rare diseases, immunology, endocrinology and hospital injectables are less exposed to simple pharmacy substitution than standard oral chronic medicines.

Retail brands remain exposed to patient co-payments. Where several products are clustered in the same reimbursement group, the lowest-price product can influence the reimbursement benchmark and increase the effective cost of higher-priced alternatives.

How large and competitive is the generic drug market in Hungary?

Hungary has a mature generic market. Generic penetration is supported by reference pricing, physician prescribing rules, pharmacy substitution and public reimbursement controls. Generic manufacturers compete on the reimbursed price, supply continuity, wholesaler relationships and physician familiarity.

The core commercial risk is price erosion. To obtain reimbursement or protect market share, a manufacturer may need to submit a price below the existing reference product. This can trigger a chain of price reductions across the therapeutic group.

What opportunities exist for generic manufacturers?

The strongest generic opportunities are in:

  • Small-molecule products losing data or market exclusivity.
  • Chronic medicines with high prescription volume.
  • Products facing shortages or limited supplier diversity.
  • Hospital medicines with fragmented competition.
  • Modified-release and complex oral dosage forms.
  • Injectable products with manufacturing barriers.
  • Fixed-dose combinations not adequately supplied by existing competitors.
  • Products where the originator has limited local commercial investment.

A generic company can also use Hungary as part of a broader European launch. A marketing authorization under the centralized procedure or a mutually recognized national authorization can support access across multiple EU markets, although each country retains control over pricing and reimbursement.

What challenges face generic companies?

Generic entry is constrained by:

  • Low reimbursement prices.
  • Reference-group price competition.
  • Mandatory public-sector discounts and deductions.
  • Delayed reimbursement decisions.
  • Tender concentration in hospital channels.
  • Parallel export and supply disruptions.
  • Local pharmacovigilance and pharmacopoeial obligations.
  • The need to coordinate launches across EU jurisdictions with different price levels.

Hungary’s relatively small market means regulatory and market-access costs can be difficult to recover when product prices are compressed.

What is the Hungarian regulatory pathway for branded and generic drugs?

The National Institute of Pharmacy and Nutrition, OGYÉI, was integrated into the National Center for Public Health and Pharmacy, NNGYK, in 2023. NNGYK is the principal Hungarian authority for national pharmaceutical oversight, including aspects of authorization, pharmacovigilance, inspections and market control (NNGYK, 2024).

Hungary uses the EU pharmaceutical framework. A product may enter through:

Authorization route Typical use
Centralized EU procedure Oncology, biologics, advanced therapies and other mandatory or strategic categories
Decentralized procedure New products seeking approval in several EU countries without an existing national authorization
Mutual recognition procedure Recognition of an existing EU national authorization
National procedure Products intended primarily for Hungary or products eligible for national authorization
Generic application Article 10 application relying on the reference product’s dossier
Hybrid application Products requiring additional clinical or bridging evidence
Biosimilar application EU biosimilar pathway with comparability evidence

A generic applicant must address pharmaceutical equivalence, bioequivalence, manufacturing compliance, labeling, pharmacovigilance and intellectual-property timing. The marketing authorization does not itself authorize commercial launch before applicable patent or supplementary protection certificate restrictions have expired.

What is the reimbursement and pricing process in Hungary?

The National Health Insurance Fund Administration decides whether a medicine receives public reimbursement. A marketing authorization is therefore only one part of market entry. Commercial launch depends on reimbursement classification, price acceptance, budget impact and prescribing conditions.

The reimbursement assessment may consider:

  • Comparative clinical benefit.
  • Cost-effectiveness.
  • Budget impact.
  • Disease prevalence.
  • Unmet medical need.
  • International reference prices.
  • The proposed reimbursement category.
  • Financial risk-sharing or outcome-based arrangements.
  • The effect on existing treatment pathways.

Hungary has used managed-entry agreements for high-cost medicines, especially in areas where clinical benefit and budget exposure require additional controls. Confidential discounts may affect the practical net price even when the publicly visible list price is higher.

Reference pricing creates a direct link between the price of a new product and existing products in the same reimbursement group. A manufacturer may secure approval but fail to obtain commercially attractive reimbursement if the authority assigns the product to a low-price reference group.

What patents protect medicines in Hungary, and when does exclusivity expire?

Hungary follows the European patent and pharmaceutical exclusivity framework. The relevant protection may include:

  • Basic compound patents.
  • Selection patents.
  • Formulation patents.
  • Dosage-regimen patents.
  • Method-of-use patents.
  • Process and manufacturing patents.
  • Supplementary protection certificates.
  • Regulatory data and market exclusivity.
  • Pediatric extensions.

Standard European patent protection generally runs for 20 years from the filing date, subject to applicable adjustments and validation. An SPC can extend protection for an authorized active substance by up to five years, with a possible six-month pediatric extension under EU rules (European Commission, 2024a).

The patent position must be assessed at the product and indication level. A compound patent may expire while a formulation or method-of-use patent remains in force. Conversely, a later patent may not block all generic versions if the generic avoids the protected claim or launches only for non-protected indications.

Does Hungary have an Orange Book?

Hungary does not operate a U.S.-style FDA Orange Book. Patent and exclusivity information must be assessed through European patent registers, the Hungarian Intellectual Property Office, SPC records, regulatory databases and court materials.

The European Medicines Agency records regulatory information for centrally authorized products, while patent validity and infringement questions are handled through national and European patent systems. Hungary is also subject to the Unified Patent Court framework for relevant European patents and unitary patents.

What Paragraph IV and generic litigation risks exist in Hungary?

Hungary does not use the U.S. Paragraph IV certification system. A generic applicant does not file a Paragraph IV certification with the Hungarian authority as a formal equivalent to the U.S. process.

The practical alternatives are:

  • Patent clearance before launch.
  • Non-infringement or invalidity analysis.
  • Declaratory proceedings.
  • Opposition or revocation actions.
  • Interim injunction applications.
  • Litigation over formulation, dosage, manufacturing or second-medical-use claims.
  • European patent opposition at the European Patent Office.
  • Unified Patent Court proceedings for patents within its jurisdiction.

A generic company may obtain marketing authorization while still facing launch risk from a patent owner. Regulatory approval and freedom to operate are separate questions.

Patent litigation risk is highest for biologics, complex formulations, inhalation products, long-acting injectables, transdermal systems and products supported by multiple secondary patents. Standard immediate-release generics generally face more predictable patent exposure but remain vulnerable to process and use patents.

What biosimilar risks and opportunities exist in Hungary?

Biosimilars are commercially attractive because Hungary faces budget pressure from high-cost biologic medicines. The opportunity is strongest in oncology, rheumatology, gastroenterology, endocrinology and supportive care.

The main regulatory pathway is the EU biosimilar framework. The European Medicines Agency evaluates comparability in quality, safety and efficacy. NNGYK participates in the EU regulatory network for products within national competence.

Biosimilar competition is affected by:

  • Physician confidence.
  • Hospital and payer tender design.
  • Interchangeability policy.
  • Treatment-naive versus switch populations.
  • Originator rebate arrangements.
  • Supply continuity.
  • Procurement concentration.
  • The extent of automatic or pharmacist-level substitution.

Hungary can accelerate biosimilar uptake through tenders and reimbursement incentives, but a low-price tender can reduce the number of viable suppliers. That creates a tension between immediate savings and long-term supply resilience.

What formulation and manufacturing IP is protected in Hungary?

Formulation patents are commercially important after basic compound patents expire. Common protected technologies include:

  • Extended-release tablets.
  • Gastro-resistant formulations.
  • Stabilized biologic formulations.
  • Device-assisted delivery.
  • Long-acting injectable systems.
  • Inhalation platforms.
  • Transdermal delivery.
  • Fixed-dose combinations.
  • Improved salt or crystal forms.

Manufacturing patents can delay or complicate generic entry where the active ingredient or finished product requires a specialized process. This is relevant for peptides, high-potency compounds, sterile injectables, complex conjugates and biologics.

Hungary is also a manufacturing and export base. Richter and Egis have domestic production capabilities, while multinational companies may use Hungary for regional supply, packaging, clinical operations or contract manufacturing. Manufacturing investment can create licensing opportunities, but facilities must comply with EU good manufacturing practice, serialization, inspection and pharmacovigilance requirements.

What is the FDA regulatory status of medicines sold in Hungary?

FDA approval is not a substitute for EU authorization. A product approved by the U.S. Food and Drug Administration still requires an EU marketing authorization or a valid national authorization before it can be marketed in Hungary.

FDA approval can support the scientific and commercial dossier, but European regulators apply EU-specific requirements for:

  • Quality and manufacturing.
  • Pharmacovigilance.
  • Pediatric obligations.
  • Labeling and package leaflets.
  • Risk-management plans.
  • Clinical-trial compliance.
  • Data exclusivity.
  • Environmental and serialization requirements.

Companies seeking parallel EU and U.S. launches should coordinate regulatory, patent and reimbursement strategies from the beginning. The U.S. launch date does not determine Hungarian launch eligibility.

What is the Orange Book status, licensing environment and settlement landscape?

There is no Hungarian Orange Book listing system. Patent status is instead assembled from European and national sources. Licensing and settlement agreements are generally private unless disclosed through financial filings, court records, competition-law materials or public procurement documents.

Relevant licensing structures include:

  • EU-wide commercialization licenses.
  • Territory-specific distribution rights.
  • Co-promotion agreements.
  • Contract manufacturing.
  • Biosimilar development partnerships.
  • In-licensing of specialty medicines.
  • Patent settlement agreements linked to delayed generic entry.

Settlements must comply with EU competition law. Agreements that delay generic entry or allocate markets can attract scrutiny if they restrict competition beyond the legitimate resolution of patent disputes. The European Commission has treated pharmaceutical patent settlements as a competition-law enforcement area (European Commission, 2024b).

What patent litigation affects the Hungarian pharmaceutical market?

Hungarian exposure can arise from:

  1. National litigation involving validated European patents.
  2. Unified Patent Court actions with territorial effect in Hungary.
  3. European Patent Office opposition proceedings.
  4. SPC disputes.
  5. Regulatory disputes over data exclusivity or marketing authorization.
  6. Competition-law investigations.
  7. Procurement challenges involving biosimilars or generic tenders.

A patent owner’s ability to obtain an injunction depends on claim scope, validity, infringement evidence, urgency and the procedural posture of the case. Commercial planning should distinguish between a theoretical patent expiry date and the date on which a competitor can safely launch.

How does Hungary compare with other Central and Eastern European markets?

Factor Hungary Poland Czech Republic Romania
Market size Small to mid-sized Largest of the four Mid-sized Large
Generic competition High High High High
Public payer influence Very high Very high High High
Pricing pressure High High High High
Hospital tender role Significant Significant Significant Significant
Regulatory framework EU EU EU EU
Reimbursement complexity High High Moderate to high High
Local manufacturing relevance High Moderate Moderate Moderate
Launch value Strategic regional market Major regional market Attractive premium relative market Large but operationally complex

Hungary is more valuable as part of a regional Central and Eastern European launch than as a standalone revenue market. Its regulatory experience, EU alignment and domestic manufacturing base make it useful for regional operations, but its reimbursement economics can be difficult for low-volume products.

What generic launch scenarios exist in Hungary?

Scenario 1: Immediate launch after basic patent expiry

This is most feasible for standard oral generics with no enforceable secondary patent, a completed reimbursement dossier and established supply capacity.

Scenario 2: Carve-out launch

A generic may launch for unprotected indications while excluding a patented indication from its label, subject to regulatory and commercial compliance. This approach requires careful packaging, promotion and prescribing controls.

Scenario 3: Delayed launch after secondary patent expiry

This applies to products with formulation, dosage or method-of-use patents that remain in force after the compound patent ends.

Scenario 4: Settlement-based launch

A generic company may agree to enter before full patent expiry under a license or settlement. The value depends on the permitted date, territory, volume restrictions and reimbursement position.

Scenario 5: Tender-led biosimilar entry

A biosimilar may secure rapid share through a hospital or payer tender. The risk is dependence on a single award and severe price compression after competing suppliers enter.

What are the main regulatory opportunities and challenges?

Opportunities

  • Centralized EU approvals with Hungarian market access.
  • Generic entry in high-volume chronic therapies.
  • Biosimilars in hospital and specialty care.
  • Shortage-driven supply opportunities.
  • Local contract manufacturing and packaging.
  • Specialty products with limited competition.
  • Digital regulatory and pharmacovigilance services.
  • Licensing of complex formulations and delivery systems.
  • Public-private partnerships for medicine supply resilience.

Challenges

  • Low net prices after reimbursement controls.
  • Mandatory deductions and payer pressure.
  • Delayed or difficult reimbursement decisions.
  • Market concentration in hospital procurement.
  • Parallel trade and supply leakage.
  • Patent disputes over secondary claims.
  • Limited market scale for niche products.
  • Frequent policy changes affecting commercial forecasts.
  • Patient affordability and adherence problems.
  • Regulatory separation between EU approval and Hungarian reimbursement.

What is the commercial outlook for branded and generic drugs?

The Hungarian market will remain structurally favorable to generics and biosimilars, but profitability will depend on differentiation, supply reliability and regional scale. Originator companies will retain strong positions in patented specialty products and high-complexity therapies, although reimbursement negotiations will limit pricing freedom.

The most resilient business models combine Hungarian registration with broader EU commercialization, local manufacturing, specialized hospital access or a differentiated formulation. Companies relying only on a low-price commodity generic face the highest margin risk.

Key Takeaways

  • Hungary is a reimbursement-led EU pharmaceutical market with high generic competition.
  • NEAK controls public reimbursement and has substantial influence over net pricing.
  • NNGYK is the principal Hungarian medicines authority after the integration of OGYÉI.
  • Hungary has no U.S.-style Orange Book and no formal Paragraph IV system.
  • Patent risk arises from European patents, SPCs, formulation claims, use patents and manufacturing claims.
  • Biosimilars have significant growth potential but face tender, substitution and price risks.
  • Local manufacturing and regional EU launches improve the commercial case for entry.
  • Generic launch timing must be based on freedom to operate, not only marketing authorization.
  • The strongest opportunities are in generics, biosimilars, specialty medicines, shortage products and complex dosage forms.
  • The principal constraints are reimbursement price erosion, public-sector deductions, tender concentration and limited market scale.

FAQs

Is Hungary a good market for generic drug launches?

Yes, when the product has meaningful prescription volume, limited competition, reliable supply and a broader Central and Eastern European launch plan. Standalone low-volume launches face weak returns because of reimbursement and price pressure.

Can a generic launch in Hungary before a European patent expires?

Only if the product does not infringe the relevant patent, a protected indication is carved out, a license permits entry, or the patent has been invalidated or otherwise rendered unenforceable. Marketing authorization alone does not remove patent risk.

Are biosimilars automatically substitutable in Hungary?

Substitution depends on Hungarian policy, product category, treatment setting and payer or hospital practice. Regulatory biosimilarity does not by itself determine automatic pharmacy-level substitution.

How long does Hungarian reimbursement approval take?

Timing varies by product category, evidence package, reimbursement route and negotiation requirements. High-cost specialty products and managed-entry applications generally require more extensive review than routine generic products.

Which companies have the strongest position in Hungary?

Richter Gedeon and Egis have the strongest domestic manufacturing and commercial positions. Multinational originators remain important in specialty, biologic and innovative therapies, while Teva, Sandoz, Viatris, Zentiva and KRKA are significant generic competitors.

References

  1. European Commission. (2024a). Supplementary protection certificates for medicinal and plant protection products. https://single-market-economy.ec.europa.eu

  2. European Commission. (2024b). Pharmaceutical sector inquiry and competition policy materials. https://competition-policy.ec.europa.eu

  3. European Medicines Agency. (2024). Biosimilar medicines: Overview and regulatory information. https://www.ema.europa.eu

  4. National Center for Public Health and Pharmacy. (2024). Medicinal product regulatory and pharmacovigilance information. https://nngyk.gov.hu

  5. National Health Insurance Fund Administration. (2024). Pharmaceutical reimbursement and supported medicinal products. https://www.neak.gov.hu

  6. Organisation for Economic Co-operation and Development. (2023). Health at a glance 2023: OECD indicators. OECD Publishing. https://doi.org/10.1787/7a7afb35-en

  7. European Patent Office. (2024). European patent and supplementary protection certificate information. https://www.epo.org

  8. Hungarian Intellectual Property Office. (2024). Patent and industrial property information. https://www.sztnh.gov.hu

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.